Clin2
NCT06188689Possibly a fitRecruiting

Testing a new diagnostic test for heart rhythm disorders

Calcium Release Deficiency Syndrome (CRDS)

Part of Heart & circulation clinical trials.

This study is evaluating a new diagnostic test for Calcium Release Deficiency Syndrome (CRDS) and related heart rhythm disorders. It aims to find out if this test can accurately identify patients with these conditions, which could lead to better diagnosis and treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
400 people
Ages
Any age
Study type
Interventional

Who can take part

  • You must have one of the following: a confirmed RyR2 gene variant that causes CRDS, or a diagnosis of CPVT, or have survived an unexplained cardiac arrest with genetic testing, or be undergoing an electrophysiology study for SVT.
  • If you have CPVT, you must meet the clinical criteria for CPVT and have a specific type of RyR2 or CASQ2 gene variant.
  • If you survived an unexplained cardiac arrest, your arrest must remain unexplained after standard tests, and you must have had genetic testing including RyR2.
  • You cannot be on certain medications: a QT-prolonging medication (except flecainide) during the test for some groups, or class I or III anti-arrhythmic drugs for controls.
  • You must be able to provide informed consent.
  • If you are a control (SVT), you must not have certain other heart conditions like ventricular cardiomyopathy or long QT syndrome.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06658899Recruiting· Phase 2
Study of CRD-4730 for CPVT (rare heart rhythm disorder)

This study tests an experimental drug called CRD-4730 for people with CPVT, a rare inherited heart rhythm disorder that can cause dangerous fast heartbeats during exercise or stress. The trial will see if the drug can help control these abnormal heart rhythms better than current treatments.

San Francisco, California
NCT06508164Recruiting
International registry for rare RYR2 variants

This study creates a registry for people with rare changes in the RYR2 gene that affect heart function. Researchers will collect information to better understand these conditions and improve care.

San Francisco, California
NCT05760924Recruiting
Testing a new heart pacing method for CRT nonresponders

This trial tests whether a different pacing approach called left bundle branch pacing can improve outcomes and heart structure changes in people who did not improve with standard biventricular CRT. It may help some patients with ongoing heart failure symptoms and weak heart pumping.

Tomsk
NCT07526896Not yet recruiting
Testing a new heart pacing method for people with heart failure

This study tests a new way to place a heart device lead to help the heart beat in sync for people with heart failure and a specific abnormal heart rhythm. The goal is to see if this method improves outcomes compared with standard treatment.

Minneapolis, Minnesota
NCT07014579Not yet recruiting
Using heart electrical signals to study treatments for dangerous heart rhythms in active people

This study looks at how the heart's electrical signals can help doctors understand if treatments prevent dangerous heart rhythms in active people. It involves people with or without heart devices like ICDs or pacemakers, and may help improve care for active individuals with heart conditions.

Leicester, Leicestershire
NCT07084467Not yet recruiting
New heart scan to improve pacemaker treatment for heart failure

This study tests a new heart scan method to help doctors place pacemakers more accurately for people with heart failure. It aims to improve the effectiveness of the pacemaker treatment and may lead to better outcomes for patients.

London

Hear when a new Calcium Release Deficiency Syndrome (CRDS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.